Pulmonx Corporation (LUNG) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.28 |
| Open | 1.26 |
| Day High | 1.29 |
| Day Low | 1.23 |
| 52-Week High | 3.88 |
| 52-Week Low | 1.13 |
| Volume | 439,690 |
| Average Volume | 428,441 |
| Market Cap | 53.64M |
| PE | -0.98 |
| EPS | -1.3 |
| Moving Average 50 Days | 1.4 |
| Moving Average 200 Days | 1.66 |
| Change | -0.01 |
Pulmonx Announces Closing of up to $60 Million Credit Facility
GlobeNewswire Inc.
Mar 04, 2026 9:05 PM GMT
Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn CapitalREDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a globa
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
GlobeNewswire Inc.
Feb 20, 2026 1:00 PM GMT
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 03, 2025 9:05 PM GMT
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”),